

Krzysztof MrÅ³zek

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9631825/publications.pdf>

Version: 2024-02-01

103
papers

13,572
citations

36691

53
h-index

37326

100
g-index

105
all docs

105
docs citations

105
times ranked

10980
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical and molecular relevance of genetic variants in the non-coding transcriptome of patients with cytogenetically normal acute myeloid leukemia. <i>Haematologica</i> , 2022, 107, 1034-1044.	1.7	4
2	Molecular, clinical, and prognostic implications of <i>PTPN11</i> mutations in acute myeloid leukemia. <i>Blood Advances</i> , 2022, 6, 1371-1380.	2.5	16
3	Effect of additional cytogenetic abnormalities on survival in arsenic trioxide-treated acute promyelocytic leukemia. <i>Blood Advances</i> , 2022, 6, 3433-3439.	2.5	5
4	Poor Survival and Differential Impact of Genetic Features of Black Patients with Acute Myeloid Leukemia. <i>Cancer Discovery</i> , 2021, 11, 626-637.	7.7	41
5	Albert de la Chapelle "pro memoriam. <i>Journal of Applied Genetics</i> , 2021, 62, 455-458.	1.0	0
6	Gene expression signature predicts relapse in adult patients with cytogenetically normal acute myeloid leukemia. <i>Blood Advances</i> , 2021, 5, 1474-1482.	2.5	20
7	Secondary cytogenetic abnormalities in core-binding factor AML harboring <i>inv(16)</i> vs <i>t(8;21)</i> . <i>Blood Advances</i> , 2021, 5, 2481-2489.	2.5	25
8	Precision oncology in AML: validation of the prognostic value of the knowledge bank approach and suggestions for improvement. <i>Journal of Hematology and Oncology</i> , 2021, 14, 107.	6.9	6
9	Phase 3 randomized trial of chemotherapy with or without oblimersen in older AML patients: CALGB 10201 (Alliance). <i>Blood Advances</i> , 2021, 5, 2775-2787.	2.5	15
10	Mutations associated with a 17-gene leukemia stem cell score and the score's prognostic relevance in the context of the European LeukemiaNet classification of acute myeloid leukemia. <i>Haematologica</i> , 2020, 105, 721-729.	1.7	21
11	Clinical and molecular characterization of patients with acute myeloid leukemia and sole trisomies of chromosomes 4, 8, 11, 13 or 21. <i>Leukemia</i> , 2020, 34, 358-368.	3.3	8
12	Mutational landscape and clinical outcome of patients with de novo acute myeloid leukemia and rearrangements involving <i>11q23/KMT2A</i> . <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 26340-26346.	3.3	59
13	Additional gene mutations may refine the 2017 European LeukemiaNet classification in adult patients with de novo acute myeloid leukemia aged ≥ 60 years. <i>Leukemia</i> , 2020, 34, 3215-3227.	3.3	66
14	Combination of dasatinib with chemotherapy in previously untreated core binding factor acute myeloid leukemia: CALGB 10801. <i>Blood Advances</i> , 2020, 4, 696-705.	2.5	44
15	Clinical and functional significance of circular RNAs in cytogenetically normal AML. <i>Blood Advances</i> , 2020, 4, 239-251.	2.5	29
16	Genetic Characterization and Prognostic Relevance of Acquired Uniparental Disomies in Cytogenetically Normal Acute Myeloid Leukemia. <i>Clinical Cancer Research</i> , 2019, 25, 6524-6531.	3.2	12
17	Implementation of standardized variant-calling nomenclature in the age of next-generation sequencing: where do we stand?. <i>Leukemia</i> , 2019, 33, 809-810.	3.3	1
18	Prognostic and Biologic Relevance of Clinically Applicable Long Noncoding RNA Profiling in Older Patients with Cytogenetically Normal Acute Myeloid Leukemia. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 1451-1459.	1.9	7

#	ARTICLE	IF	CITATIONS
19	Expression and functional relevance of long non-coding RNAs in acute myeloid leukemia stem cells. <i>Leukemia</i> , 2019, 33, 2169-2182.	3.3	52
20	Complex karyotype in de novo acute myeloid leukemia: typical and atypical subtypes differ molecularly and clinically. <i>Leukemia</i> , 2019, 33, 1620-1634.	3.3	55
21	Mutation patterns identify adult patients with de novo acute myeloid leukemia aged 60 years or older who respond favorably to standard chemotherapy: an analysis of Alliance studies. <i>Leukemia</i> , 2018, 32, 1338-1348.	3.3	80
22	Ten-year outcome of patients with acute myeloid leukemia not treated with allogeneic transplantation in first complete remission. <i>Blood Advances</i> , 2018, 2, 1645-1650.	2.5	85
23	Randomized trial of 10 days of decitabine ± bortezomib in untreated older patients with AML: CALGB 11002 (Alliance). <i>Blood Advances</i> , 2018, 2, 3608-3617.	2.5	39
24	Core-binding factor acute myeloid leukemia with t(8;21): Risk factors and a novel scoring system (Iâ€•CBF) Tj ETQq0 0 0 rgBT /Overlo	1.8	17
25	NF1 mutations are recurrent in adult acute myeloid leukemia and confer poor outcome. <i>Leukemia</i> , 2018, 32, 2536-2545.	3.3	33
26	Prognostic impact of the CD34+/CD38âˆ’ cell burden in patients with acute myeloid leukemia receiving allogeneic stem cell transplantation. <i>American Journal of Hematology</i> , 2017, 92, 388-396.	2.0	25
27	Prognostic and biologic significance of long non-coding RNA profiling in younger adults with cytogenetically normal acute myeloid leukemia. <i>Haematologica</i> , 2017, 102, 1391-1400.	1.7	28
28	Prognostic and biological significance of the proangiogenic factor EGFL7 in acute myeloid leukemia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E4641-E4647.	3.3	36
29	Mutational Landscape and Gene Expression Patterns in Adult Acute Myeloid Leukemias with Monosomy 7 as a Sole Abnormality. <i>Cancer Research</i> , 2017, 77, 207-218.	0.4	23
30	Chromosome abnormalities at onset of complete remission are associated with worse outcome in patients with acute myeloid leukemia and an abnormal karyotype at diagnosis: CALGB 8461 (Alliance). <i>Haematologica</i> , 2016, 101, 1516-1523.	1.7	13
31	Persistence of DNMT3A R882 mutations during remission does not adversely affect outcomes of patients with acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2016, 175, 226-236.	1.2	49
32	Deregulation of DUX4 and ERG in acute lymphoblastic leukemia. <i>Nature Genetics</i> , 2016, 48, 1481-1489.	9.4	231
33	Acute Myeloid Leukemia. , 2016, , 527-559.		0
34	Chromosome Abnormalities in Acute Myeloid Leukaemia and Their Clinical Importance. , 2015, , 275-317.		2
35	Intensive induction is effective in selected octogenarian acute myeloid leukemia patients: prognostic significance of karyotype and selected molecular markers used in the European LeukemiaNet classification. <i>Haematologica</i> , 2014, 99, 308-313.	1.7	32
36	Expression and prognostic impact of lncRNAs in acute myeloid leukemia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 18679-18684.	3.3	214

#	ARTICLE	IF	CITATIONS
37	Epigenetics Meets Genetics in Acute Myeloid Leukemia: Clinical Impact of a Novel Seven-Gene Score. <i>Journal of Clinical Oncology</i> , 2014, 32, 548-556.	0.8	134
38	GAS6 expression identifies high-risk adult AML patients: potential implications for therapy. <i>Leukemia</i> , 2014, 28, 1252-1258.	3.3	45
39	SPARC promotes leukemic cell growth and predicts acute myeloid leukemia outcome. <i>Journal of Clinical Investigation</i> , 2014, 124, 1512-1524.	3.9	52
40	New recurrent balanced translocations in acute myeloid leukemia and myelodysplastic syndromes: Cancer and leukemia group B 8461. <i>Genes Chromosomes and Cancer</i> , 2013, 52, 385-401.	1.5	13
41	Reply to K. Orendi et al. <i>Journal of Clinical Oncology</i> , 2013, 31, 2361-2362.	0.8	1
42	Clinical Role of microRNAs in Cytogenetically Normal Acute Myeloid Leukemia: <i>miR-155</i> Upregulation Independently Identifies High-Risk Patients. <i>Journal of Clinical Oncology</i> , 2013, 31, 2086-2093.	0.8	165
43	<i>inv(16)/t(16;16)</i> acute myeloid leukemia with non-“type A CBFβ-MYH11 fusions associate with distinct clinical and genetic features and lack KIT mutations. <i>Blood</i> , 2013, 121, 385-391.	0.6	39
44	Prognostic Significance of the European LeukemiaNet Standardized System for Reporting Cytogenetic and Molecular Alterations in Adults With Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2012, 30, 4515-4523.	0.8	363
45	<i>miR-3151</i> interplays with its host gene BAALC and independently affects outcome of patients with cytogenetically normal acute myeloid leukemia. <i>Blood</i> , 2012, 120, 249-258.	0.6	64
46	<i>RUNX1</i> Mutations Are Associated With Poor Outcome in Younger and Older Patients With Cytogenetically Normal Acute Myeloid Leukemia and With Distinct Gene and MicroRNA Expression Signatures. <i>Journal of Clinical Oncology</i> , 2012, 30, 3109-3118.	0.8	242
47	Age-Related Prognostic Impact of Different Types of <i>DNMT3A</i> Mutations in Adults With Primary Cytogenetically Normal Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2012, 30, 742-750.	0.8	244
48	Acute myeloid leukemia with adverse cytogenetic risk. <i>Oncology</i> , 2012, 26, 714, 723.	0.4	1
49	Diagnostic and Prognostic Value of Cytogenetics in Acute Myeloid Leukemia. <i>Hematology/Oncology Clinics of North America</i> , 2011, 25, 1135-1161.	0.9	87
50	<i>TET2</i> Mutations Improve the New European LeukemiaNet Risk Classification of Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study. <i>Journal of Clinical Oncology</i> , 2011, 29, 1373-1381.	0.8	291
51	Clinical outcome and gene- and microRNA-expression profiling according to the Wilms tumor 1 (WT1) single nucleotide polymorphism rs16754 in adult de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. <i>Haematologica</i> , 2011, 96, 1488-1495.	1.7	20
52	Low expression of MN1 associates with better treatment response in older patients with de novo cytogenetically normal acute myeloid leukemia. <i>Blood</i> , 2011, 118, 4188-4198.	0.6	52
53	ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category. <i>Blood</i> , 2011, 118, 6920-6929.	0.6	246
54	The prognostic and functional role of microRNAs in acute myeloid leukemia. <i>Blood</i> , 2011, 117, 1121-1129.	0.6	247

#	ARTICLE	IF	CITATIONS
55	Mutations of the Wilms tumor 1 gene (WT1) in older patients with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. <i>Blood</i> , 2010, 116, 788-792.	0.6	80
56	FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. <i>Blood</i> , 2010, 116, 3622-3626.	0.6	201
57	Prognostic Significance of Expression of a Single MicroRNA, <i>miR-181a</i> , in Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study. <i>Journal of Clinical Oncology</i> , 2010, 28, 5257-5264.	0.8	176
58	<i>IDH1</i> and <i>IDH2</i> Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study. <i>Journal of Clinical Oncology</i> , 2010, 28, 2348-2355.	0.8	699
59	BAALC and ERG expression levels are associated with outcome and distinct gene and microRNA expression profiles in older patients with de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. <i>Blood</i> , 2010, 116, 5660-5669.	0.6	110
60	Favorable Prognostic Impact of <i>NPM1</i> Mutations in Older Patients With Cytogenetically Normal De Novo Acute Myeloid Leukemia and Associated Gene- and MicroRNA-Expression Signatures: A Cancer and Leukemia Group B Study. <i>Journal of Clinical Oncology</i> , 2010, 28, 596-604.	0.8	305
61	Molecular signatures in acute myeloid leukemia. <i>Current Opinion in Hematology</i> , 2009, 16, 64-69.	1.2	41
62	Prognostic Importance of <i>MN1</i> Transcript Levels, and Biologic Insights From <i>MN1</i> -Associated Gene and MicroRNA Expression Signatures in Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study. <i>Journal of Clinical Oncology</i> , 2009, 27, 3198-3204.	0.8	149
63	MicroRNA expression in acute myeloid leukemia. <i>Current Hematologic Malignancy Reports</i> , 2009, 4, 83-88.	1.2	44
64	MicroRNA expression profiling in acute myeloid and chronic lymphocytic leukaemias. <i>Best Practice and Research in Clinical Haematology</i> , 2009, 22, 239-248.	0.7	26
65	Acquired copy number alterations in adult acute myeloid leukemia genomes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 12950-12955.	3.3	231
66	Cytogenetics and Molecular Genetics of Acute Lymphoblastic Leukemia. <i>Hematology/Oncology Clinics of North America</i> , 2009, 23, 991-1010.	0.9	115
67	Cytogenetic, Molecular Genetic, and Clinical Characteristics of Acute Myeloid Leukemia With a Complex Karyotype. <i>Seminars in Oncology</i> , 2008, 35, 365-377.	0.8	138
68	Advances in molecular genetics and treatment of core-binding factor acute myeloid leukemia. <i>Current Opinion in Oncology</i> , 2008, 20, 711-718.	1.1	79
69	Low-Dose Interleukin-2 Immunotherapy Does Not Improve Outcome of Patients Age 60 Years and Older With Acute Myeloid Leukemia in First Complete Remission: Cancer and Leukemia Group B Study 9720. <i>Journal of Clinical Oncology</i> , 2008, 26, 4934-4939.	0.8	114
70	MicroRNA Expression in Cytogenetically Normal Acute Myeloid Leukemia. <i>New England Journal of Medicine</i> , 2008, 358, 1919-1928.	13.9	427
71	Wilms Tumor 1 Gene Mutations Independently Predict Poor Outcome in Adults With Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study. <i>Journal of Clinical Oncology</i> , 2008, 26, 4595-4602.	0.8	230
72	Prognostic Significance of, and Gene and MicroRNA Expression Signatures Associated With, <i>CEBPA</i> Mutations in Cytogenetically Normal Acute Myeloid Leukemia With High-Risk Molecular Features: A Cancer and Leukemia Group B Study. <i>Journal of Clinical Oncology</i> , 2008, 26, 5078-5087.	0.8	294

#	ARTICLE	IF	CITATIONS
73	Clinical Significance of the Most Common Chromosome Translocations in Adult Acute Myeloid Leukemia. <i>Journal of the National Cancer Institute Monographs</i> , 2008, 2008, 52-57.	0.9	43
74	FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications. <i>Blood</i> , 2008, 111, 1552-1559.	0.6	243
75	High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) study. <i>Blood</i> , 2008, 111, 5371-5379.	0.6	174
76	Central review of cytogenetics is necessary for cooperative group correlative and clinical studies of adult acute leukemia: the Cancer and Leukemia Group B experience. <i>International Journal of Oncology</i> , 2008, 33, 239-44.	1.4	50
77	High Expression Levels of the ETS-Related Gene, ERG, Predict Adverse Outcome and Improve Molecular Risk-Based Classification of Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study. <i>Journal of Clinical Oncology</i> , 2007, 25, 3337-3343.	0.8	184
78	Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification?. <i>Blood</i> , 2007, 109, 431-448.	0.6	507
79	Long-term disease-free survivors with cytogenetically normal acute myeloid leukemia and MLL partial tandem duplication: a Cancer and Leukemia Group B study. <i>Blood</i> , 2007, 109, 5164-5167.	0.6	92
80	Influence of new molecular prognostic markers in patients with karyotypically normal acute myeloid leukemia: recent advances. <i>Current Opinion in Hematology</i> , 2007, 14, 106-114.	1.2	66
81	Clinical outcome of de novo acute myeloid leukaemia patients with normal cytogenetics is affected by molecular genetic alterations: a concise review. <i>British Journal of Haematology</i> , 2007, 137, 387-400.	1.2	97
82	Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461. <i>Blood</i> , 2006, 108, 63-73.	0.6	285
83	Independent confirmation of a prognostic gene-expression signature in adult acute myeloid leukemia with a normal karyotype: a Cancer and Leukemia Group B study. <i>Blood</i> , 2006, 108, 1677-1683.	0.6	123
84	Chromosome Aberrations, Gene Mutations and Expression Changes, and Prognosis in Adult Acute Myeloid Leukemia. <i>Hematology American Society of Hematology Education Program</i> , 2006, 2006, 169-177.	0.9	107
85	Cancer and Leukemia Group B Leukemia Correlative Science Committee: Major Accomplishments and Future Directions: Table 1.. <i>Clinical Cancer Research</i> , 2006, 12, 3564s-3571s.	3.2	11
86	Adverse Prognostic Significance of KIT Mutations in Adult Acute Myeloid Leukemia With inv(16) and t(8;21): A Cancer and Leukemia Group B Study. <i>Journal of Clinical Oncology</i> , 2006, 24, 3904-3911.	0.8	618
87	Molecular heterogeneity and prognostic biomarkers in adults with acute myeloid leukemia and normal cytogenetics. <i>Current Opinion in Hematology</i> , 2005, 12, 68-75.	1.2	110
88	Overexpression of the ETS-Related Gene, ERG, Predicts a Worse Outcome in Acute Myeloid Leukemia With Normal Karyotype: A Cancer and Leukemia Group B Study. <i>Journal of Clinical Oncology</i> , 2005, 23, 9234-9242.	0.8	226
89	Outcome of Induction and Postremission Therapy in Younger Adults With Acute Myeloid Leukemia With Normal Karyotype: A Cancer and Leukemia Group B Study. <i>Journal of Clinical Oncology</i> , 2005, 23, 482-493.	0.8	119
90	Prognostic Factors and Outcome of Core Binding Factor Acute Myeloid Leukemia Patients With t(8;21) Differ From Those of Patients With inv(16): A Cancer and Leukemia Group B Study. <i>Journal of Clinical Oncology</i> , 2005, 23, 5705-5717.	0.8	324

#	ARTICLE	IF	CITATIONS
91	Acute myeloid leukemia with complex karyotypes and abnormal chromosome 21: Amplification discloses overexpression of APP, ETS2, and ERG genes. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 3915-3920.	3.3	155
92	Repetitive Cycles of High-Dose Cytarabine Benefit Patients With Acute Myeloid Leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): Results from CALGB 8461. Journal of Clinical Oncology, 2004, 22, 1087-1094.	0.8	190
93	Abnormal Cytogenetics at Date of Morphologic Complete Remission Predicts Short Overall and Disease-Free Survival, and Higher Relapse Rate in Adult Acute Myeloid Leukemia: Results From Cancer and Leukemia Group B Study 8461. Journal of Clinical Oncology, 2004, 22, 2410-2418.	0.8	101
94	Cytogenetics in acute leukemia. Blood Reviews, 2004, 18, 115-136.	2.8	600
95	Additional cytogenetic abnormalities in adults with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a study of the Cancer and Leukaemia Group AB. British Journal of Haematology, 2004, 124, 275-288.	1.2	78
96	Molecular cytogenetic characterization of the KG-1 and KG-1a acute myeloid leukemia cell lines by use of spectral karyotyping and fluorescence in situ hybridization. Genes Chromosomes and Cancer, 2003, 38, 249-252.	1.5	27
97	Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood, 2002, 100, 4325-4336.	0.6	1,444
98	Spectral karyotyping in patients with acute myeloid leukemia and a complex karyotype shows hidden aberrations, including recurrent overrepresentation of 21q, 11q, and 22q. Genes Chromosomes and Cancer, 2002, 34, 137-153.	1.5	90
99	Isolated trisomy of chromosomes 8, 11, 13 and 21 is an adverse prognostic factor in adults with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B 8461. International Journal of Oncology, 2002, 21, 1041-51.	1.4	13
100	Clinical importance of cytogenetics in acute myeloid leukaemia. Best Practice and Research in Clinical Haematology, 2001, 14, 19-47.	0.7	162
101	Comparison of Cytogenetic and Molecular Genetic Detection of t(8;21) and inv(16) in a Prospective Series of Adults With De Novo Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study. Journal of Clinical Oncology, 2001, 19, 2482-2492.	0.8	94
102	Spectral karyotyping reveals 17;22 fusions in a cytogenetically atypical dermatofibrosarcoma protuberans with a large marker chromosome as a sole abnormality. Genes Chromosomes and Cancer, 2001, 31, 182-186.	1.5	10
103	Central review of cytogenetics is necessary for cooperative group correlative and clinical studies of adult acute leukemia: the Cancer and Leukemia Group B experience. International Journal of Oncology, 1992, 33, 239.	1.4	25